Osteoclast activity and bone resorption pathways

Osteoclast activity and bone resorption pathways refer to the physiological processes by which specialized bone-resorbing cells, osteoclasts, break down and remove bone tissue (StatPearls, 2023). This process is a critical component of bone remodeling, allowing for the repair of micro-damage and the maintenance of systemic calcium levels (NIH, 2022). The pathway is primarily governed by the interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), its receptor RANK, and the decoy receptor Osteoprotegerin (OPG) (UniProt, 2024). When bone resorption exceeds bone formation, it leads to skeletal fragility and diseases such as osteoporosis, Paget's disease, and bone metastases (PubMed, 2019). Therapeutic strategies targeting these pathways include bisphosphonates, which bind to bone mineral and inhibit osteoclast function, and denosumab, a monoclonal antibody that neutralizes RANKL (FDA, 2023). Monitoring these pathways often involves measuring biochemical markers of bone turnover, such as C-terminal telopeptide (CTX) (Vasikaran et al., 2011).

Other names

Bone resorptionOsteoclastogenesisRANK/RANKL/OPG signaling pathwayOsteoclastic bone resorption

Inhibition of osteoclast differentiation and activation via RANKL neutralization (e.g., denosumab), induction of osteoclast apoptosis through bisphosphonate binding to hydroxyapatite and inhibition of the mevalonate pathway, and inhibition of bone matrix degradation by blocking proteases like Cathepsin K (StatPearls, 2023; Russell, 2011).